SARS-CoV-2 Mpro-IN-2

Research use only, not for human use.

SARS-CoV-2 Mpro-IN-2 is a selective SARS-CoV-2M pro inhibitor with an IC50 value of 0.40 μM.SARS-CoV-2 Mpro-IN-2 has good antiviral activity and can be used to study COVID-19.

SARS-CoV-2 Mpro-IN-2 (compound GC-14) is a selective, low cytotoxic and non-covalent Mpro inhibitor (IC50=0.40 μM) with good anti-SARS-CoV-2 activity (EC50=1.1 μM). SARS-CoV-2 Mpro-IN-2 can be used in COVID-19 studies.

SARS-CoV-2 Mpro-IN-2 (0.01-100 μM; 4 h) shows low cytotoxicity in Vero E6 cells.Cell Cytotoxicity Assay Cell Line:Vero E6 cells Concentration:0.01-100 μM Incubation Time:4 h Result:Exhibited low cytotoxicity with a CC50 value of more than 100 μM.

SARS-CoV-2 Mpro-IN-2 (2 mg/kg; i.v.; single) exhibits clearance rate (CL), mean residence time (MRT), and half-life (t1/2) are 3140 mL/h/kg, 0.40 h, and 0.36 h, respectively.SARS-CoV-2 Mpro-IN-2 (10 mg/kg; p.o.; single) is rapidly absorbed, with a time-to-maximum concentration (Tmax) of 0.5 h, and shows a moderate pharmacokinetic profile including a favorable t1/2 (1.73 h), a maximum concentration (Cmax) 74.6 ng/mL, and an area under curve (AUC0-t) of 235 ng h/mL.Animal Model:Male Sprague-Dawley rats.Dosage:2 mg/kg (for i.v.); 10 mg/kg (for p.o.).Administration:Intravenous injection or oral administration; single.

——

Others

Other Targets

SARS-CoV

——

——

2768834-39-3

475.39

C22H20Cl2N4O2S

>98% (HPLC)

——

C(NCC1=CC=CS1)(=O)[C@H]2N(CCN(C(=O)C=3C=CC=NC3)C2)C4=CC(Cl)=C(Cl)C=C4

——

(-20℃)

With Ice Pack

≥ 2 years